Personalis

Personalis, Inc. is a provider of advanced genomic sequencing and analysis solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies.Our patented ACE (Accuracy and Content Enhancement) Technology forms the foundation of all Personalis products. ACE Technology improves every step of the next-generation sequencing (NGS) process, from nucleic acid extraction to sequencing assays and data analysis. This enables expanded coverage of difficult-to-sequence genomic regions that are inaccessible with conventional sequencing methods.Using this comprehensive approach, we deliver genomic data of the highest quality and accuracy to help biopharmaceutical companies advance their immuno-oncology clinical and biomarker discovery programs, enabling the rational design and development of effective cancer immunotherapies.Personalis was spun out of Stanford University in 2011 by a group of internationally recognized NGS thought leaders, including John West (our CEO), Dr. Euan Ashley, Dr. Atul Butte, Dr. Russ Altman, and Dr. Michael Snyder. Our headquarters is located in Menlo Park, California, where we operate our CLIA-certified, CAP-accredited laboratory.